Lead Product(s): SYT-510
Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Ysios Capital
Deal Size: $26.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 20, 2021
This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.